Literature DB >> 6318670

Efficacy of ketoconazole in cutaneous leishmaniasis.

L Weinrauch, R Livshin, Z Even-Paz, J El-On.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6318670     DOI： 10.1007/bf00417211

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN： 0340-3696            Impact factor:   3.017


× No keyword cloud information.
  6 in total

1.  Treatment of cutaneous leishmaniasis with trimethoprim-sulfamethoxazole combination.

Authors:  E Kandil
Journal:  Dermatologica       Date:  1973

2.  Activity of imidazoles against Leishmania tropica in human macrophage cultures.

Authors:  J D Berman
Journal:  Am J Trop Med Hyg       Date:  1981-05       Impact factor: 2.345

3.  [Metronidazole therapy of cutaneous leishmaniasis].

Authors:  O A Baabbad
Journal:  Med Parazitol (Mosk)       Date:  1981 Jan-Feb

4.  Oral ketoconazole in the treatment of leishmaniasis.

Authors:  F G Urcuyo; N Zaias
Journal:  Int J Dermatol       Date:  1982-09       Impact factor: 2.736

5.  Therapy of tropical skin diseases.

Authors:  A Bryceson
Journal:  Clin Exp Dermatol       Date:  1981-09       Impact factor: 3.470

6.  Rifampicin treatment of cutaneous leishmaniasis.

Authors:  Z Even-Paz; L Weinrauch; R Livshin; J El-On; C L Greenblatt
Journal:  Int J Dermatol       Date:  1982-03       Impact factor: 2.736
  6 in total
  8 in total

Review 1.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-11-17

2.  Cutaneous leishmaniasis: failure of topical treatment with imidazole derivatives in laboratory animals and man.

Authors:  L Weinrauch; R Livshin; G P Jacobs; J El-On
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

3.  Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes.

Authors:  H Rangel; F Dagger; A Hernandez; A Liendo; J A Urbina
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

Review 4.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

Review 5.  Interventions for Old World cutaneous leishmaniasis.

Authors:  Julio Heras-Mosteiro; Begoña Monge-Maillo; Mariona Pinart; Patricia Lopez Pereira; Ludovic Reveiz; Emely Garcia-Carrasco; Pedro Campuzano Cuadrado; Ana Royuela; Irene Mendez Roman; Rogelio López-Vélez
Journal:  Cochrane Database Syst Rev       Date:  2017-12-01

6.  Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide.

Authors:  Caspar J Hodiamont; Piet A Kager; Aldert Bart; Henry J C de Vries; Pieter P A M van Thiel; Tjalling Leenstra; Peter J de Vries; Michèle van Vugt; Martin P Grobusch; Tom van Gool
Journal:  PLoS Negl Trop Dis       Date:  2014-05-01

Review 7.  Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.

Authors:  Rajamanthrilage Kasun Madusanka; Hermali Silva; Nadira D Karunaweera
Journal:  Infect Dis Ther       Date:  2022-02-22

Review 8.  Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis.

Authors:  Endi Lanza Galvão; Ana Rabello; Gláucia Fernandes Cota
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.